Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.

NOVAN CHART 052220

Upward 1-2-3 waves formed. Once restore 0.41, a critical gateway level, this will reach again previous high. Looks great.